Hansa Biopharma (HNSA.ST) Stock Analysis & AI Equity Report
Hansa Biopharma (HNSA.ST) overview
Hansa Biopharma (HNSA.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Hansa Biopharma reported revenue of SEK 222m and operating profit of SEK -521m; the year-end share price was 34.36 SEK and market capitalisation was SEK 2,790m. Hansa Biopharma is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Hansa Biopharma's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Hansa Biopharma
Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes immunomodulating therapies for rare immunological conditions. Its proprietary antibody-cleaving enzyme platform includes imlifidase and HNSA-5487, with applications in transplantation, autoimmune diseases and gene therapy. The company is based in Lund, Sweden and operates in Europe and the United States.
Generate the Hansa Biopharma report
Hansa Biopharma is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Hansa Biopharma and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Hansa Biopharma
Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.